Tandon Puneeta, Tangri Navdeep, Thomas Lesley, Zenith Laura, Shaikh Tahira, Carbonneau Michelle, Ma Mang, Bailey Robert J, Jayakumar Saumya, Burak Kelly W, Abraldes Juan G, Brisebois Amanda, Ferguson Thomas, Majumdar Sumit R
Cirrhosis Care Clinic, University of Alberta, Edmonton, Alberta, Canada.
Division of Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada.
Am J Gastroenterol. 2016 Dec;111(12):1759-1767. doi: 10.1038/ajg.2016.303. Epub 2016 Aug 2.
Screening tools to determine which outpatients with cirrhosis are at highest risk for unplanned hospitalization are lacking. Frailty is a novel prognostic factor but conventional screening for frailty is time consuming. We evaluated the ability of a 1 min bedside screen (Clinical Frailty Scale (CFS)) to predict unplanned hospitalization or death in outpatients with cirrhosis and compared the CFS with two conventional frailty measures (Fried Frailty Criteria (FFC) and Short Physical Performance Battery (SPPB)).
We prospectively enrolled consecutive outpatients from three tertiary care liver clinics. Frailty was defined by CFS >4. The primary outcome was the composite of unplanned hospitalization or death within 6 months of study entry.
A total of 300 outpatients were enrolled (mean age 57 years, 35% female, 81% white, 66% hepatitis C or alcohol-related liver disease, mean Model for End-Stage Liver Disease (MELD) score 12, 28% with ascites). Overall, 54 (18%) outpatients were frail and 91 (30%) patients had an unplanned hospitalization or death within 6 months. CFS >4 was independently associated with increased rates of unplanned hospitalization or death (57% frail vs. 24% not frail, adjusted odds ratio 3.6; 95% confidence interval (CI): 1.7-7.5; P=0.0008) and there was a dose response (adjusted odds ratio 1.9 per 1-unit increase in CFS, 95% CI: 1.4-2.6; P<0.0001). Models including MELD, ascites, and CFS >4 had a greater discrimination (c-statistic=0.84) than models using FFC or SPPB.
Frailty is strongly and independently associated with an increased risk of unplanned hospitalization or death in outpatients with cirrhosis. The CFS is a rapid screen that could be easily adopted in liver clinics to identify those at highest risk of adverse events.
目前缺乏用于确定哪些肝硬化门诊患者发生非计划住院风险最高的筛查工具。衰弱是一种新的预后因素,但传统的衰弱筛查耗时较长。我们评估了1分钟床边筛查(临床衰弱量表(CFS))预测肝硬化门诊患者非计划住院或死亡的能力,并将CFS与两种传统的衰弱评估方法(弗里德衰弱标准(FFC)和简短体能测试电池(SPPB))进行比较。
我们前瞻性地纳入了来自三家三级医疗肝病诊所的连续门诊患者。衰弱定义为CFS>4。主要结局是在研究入组后6个月内非计划住院或死亡的复合情况。
共纳入300例门诊患者(平均年龄57岁,35%为女性,81%为白人,66%为丙型肝炎或酒精性肝病,终末期肝病模型(MELD)评分平均为12,28%有腹水)。总体而言,54例(18%)门诊患者衰弱,91例(30%)患者在6个月内发生非计划住院或死亡。CFS>4与非计划住院或死亡发生率增加独立相关(57%衰弱患者与24%非衰弱患者,校正比值比3.6;95%置信区间(CI):1.7 - 7.5;P = 0.0008),且存在剂量反应(CFS每增加1个单位,校正比值比为1.9,95% CI:1.4 - 2.6;P < 0.0001)。包括MELD、腹水和CFS>4的模型比使用FFC或SPPB的模型具有更好的区分度(c统计量 = 0.84)。
衰弱与肝硬化门诊患者非计划住院或死亡风险增加密切且独立相关。CFS是一种快速筛查工具,可在肝病诊所轻松采用以识别发生不良事件风险最高的患者。